- ASSOCIATE PROFESSOR Ophthalmology
M.D., Shanghai Medical University
Hua Shan Hospital, Shanghai Medical University
Gau Su Province People's Hospital
M.S., Eye and ENT Hospital Shanghai Medical University
New York Eye and Ear Infirmary
The Mount Sinai Medical Center
Dr. Wang's major research field is on glaucoma pharmacology. Her studies encompass the development new anti-glaucoma drugs and elucidation of the mechanism of action of ocular hypotensive agents, testing different kinds of new potential drugs in normal and glaucomatous monkeys. This is very important procedure to predict a clinical response of new potential drugs in glaucoma patients.
Currently, lowering intraocular pressure (IOP) is the only established effective treatment for glaucoma patients. Medications are usually considered the first line treatment for glaucoma. In the past decade, several experimental compounds investigated in the glaucoma laboratory have been released for clinical treatment of glaucoma. These are Trusopt, a topical carbonic anhydrase inhibitor; Xalatan, a prostaglandin F2? analog; Alphagan, a ?2-adrenergic agonist. These new drugs have greatly enhanced the options for the medical treatment of glaucoma.
Dr. Wang received her M.S. in Genetics of Ophthalmology in 1982 and her M.D. from Faculty of Medicine in 1969, both from Shanghai Medical University. Her M.S. thesis received achievement award from the Ministry of National Health of The People's Republic of China. Before she arrived in the United States, she was an Attending Doctor and Assistant Professor at Eye and ENT Hospital of Shanghai Medical University.
When she arrived in New York, Dr. Wang was a Clinical Research Fellow in Glaucoma at the New York Eye and Ear Infirmary. She has joined Mount Sinai in the department of ophthalmology since 1986.
Dr. Wang is a productive research scientist. Many of her work have been published in Archives of ophthalmology, which ranks first among clinical ophthalmology with the greatest impact in over 95 countries.
Dr. Wang has given invited lectures on the international conference in China. Currently, she in on the editorial board of Journal of Chinese Ophthalmology and Otolaryngology.
Searching for the new classes of anti-glaucoma drugs that are different from currently clinical used drugs.
Glaucoma is a progressive optic neuropathy and not a pressure disease. Lowering IOP provides only partial solution to treating this blinding disease. Thus, searching for a new therapeutic way that can provide neuroprotection or neurorepair is our target.
Wang RF, Lee PY, Mittag TW, Podos SM, Serle JB. Effect of 5-methylurapidil, an I?1A-adrenergic antagonist and 5-hydroxytryptamine1a (serotonin) agonist, on aqueous humor dynamics in monkeys. Curr Eye Res 1997 Aug; 16(8): 769-75.
Wang RF, Lee PY, Mittag TW, Podos SM, Serle JB, Becker B. Effect of 8-iso prostaglandin E2 on aqueous humor dynamics in monkeys. Arch Ophthalmol 1998 Sep; 116(9): 1213-6.
Wang RF, Schumer RA, Serle JB, Podos SM. A comparison of argon laser and diode laser photocoagulation of trabecular meshwork to produce the glaucoma monkey model. J Glaucoma 1998 Feb; 7(1): 45-9.
Wang RF, Podos SM, Serle JB, Mittag TW, Ventosa F, Becker B. Ventosa F, Becker B. Effect of latanoprost or 8-iso prostaglandin E2 alone and in combination on intraocular pressure in glaucomatous monkey eyes. Arch Ophthalmol 2000 Jan; 118(1): 74-7.
Wang RF, Serle JB, Gagliuso DJ, Podos SM. Comparison of ocular hypotensive effect of brimonidine, dorzolamide, latanoprost or artificial tears added to timolol in glaucomatous monkey eyes. J Glaucoma 2000 Dec; 9(62): 458-62.
Serle JB, Wang RF, Mittag TW, Shen F, Podos SM. Effect of pilocarpine 4% in combination with latanoprost 0.005% or 8-iso prostaglandin E2 0.1% on intraocular pressure in laser-induced glaucomatous monkey eyes. J Glaucoma 2001 Jun; 10(3): 215-9.
Chien FY, Wang RF, Mittag TW, Podos SM. Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys. Arch Ophthalmol 2003 Jan; 121(1): 87-90.
Tian B, Wang RF, Podos SM, Kaufman PL. Effects of topical H-7 on outflow facility, intraocular pressure, and corneal thickness in monkeys. Arch Ophthalmol 2004 Aug; 122(8): 1171-7.
Gagliuso DJ, Wang RF, Mittag TW, Podos SM. Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkeys eyes. Arch Ophthalmol 2004 Sep; 122(9): 1342-7.
Wang RF, Podos SM, Mittag TW, Yokoyoma T. Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes. Exp Eye Res 2005 May; 80(5): 629-32.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Wang did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.